Ticagrelor Not Better Than Aspirin for Preventing CV Events — Physician’s First Watch

Medical News |
March 25, 2016

Ticagrelor Not Better Than Aspirin for Preventing CV Events

By Amy Orciari Herman

Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS

The antiplatelet ticagrelor (Brilinta) is no better than aspirin for preventing cardiovascular events in patients with acute ischemic stroke or transient ischemic attack, the manufacturer announced on Wednesday.

In the international SOCRATES trial, adults aged 40 and older who'd had a stroke or TIA within the past 24 hours were randomized to receive ticagrelor (90 mg twice daily) or aspirin (100 mg once daily) for 90 days. The primary efficacy endpoint was the time to first occurrence of stroke (ischemic or hemorrhagic), myocardial infarction, or death.

The manufacturer said that while fewer endpoint events occurred with ticagrelor, the difference between groups was not statistically significant.

Reader Comments (1)

Sonal Physician, Cardiology

What about role of ticagrelor in secondary prevention of stroke or TIA?

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.